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ABSTRACT  
 
Backround: Primary high grade non-Hodgkin lymphoma of the female genital tract is 
extremely rare. Vaginal bleeding, abdominal pain or urinary complaints might be its most 
frequent symptoms.  
Case: We report a 27-year-old multipara who underwent large loop excision of the 
transformation zone because of the repeated finding of low grade squamous 
intraepithelial lesion identified during routine cancer screening. Incidentally, CD20 
positive, primary, diffuse large B-cell lymphoma infiltrating the mucosa of the 
endocervix was also diagnosed from this specimen. The case is unusual because the 
patient had no symptoms, specific colposcopic signs or a visible mass. R-CHOP 21 
immunochemotherapy was introduced and resulted in complete remission without 
hysterectomy. The patient is without evidence of disease after 36 months of follow-up . 
Conclusion: Primary cervical lymphomas are mainly subepithelial initially, therefore they 
may be underrecognized due to the inefficiency of smears to diagnose such lesions. Early 
diagnosis and available targeted treatment allowed a cure in the reported example. 
 
 
 
Established Facts: 
 Already known: Primary high grade non-Hodgkin lymphoma of the female genital tract is 
extremely rare. 
 Already known: Vaginal bleeding, abdominal pain, urinary complaints and vaginal or 
cervicovaginal or pelvic mass are the frequent primary symptom of genital lymphomas. 
 
 
Novel Insights: 
 New information: The case is unusual because the patient had no symptoms, specific 
colposcopic signs or a visible mass.  
 New information: Cervical cytology has only a limited role in establishing the proper 
diagnosis, which can be best made on the basis of LLETZ. Although the introduced 
patient's management was deviated from standard gynecological cancer screening 
protocols, this led to reveal the hidden disease at an early stage. 
 New information: It is still unknown whether chemotherapy alone or in combination with 
radiotherapy or surgical interventions would be the optimal therapeutic approach. In this 
case R-CHOP 21 immunochemotherapy was introduced and resulted in complete 
remission without hysterectomy. 
 
 
3 
 
INTRODUCTION: 
 
Primary non-Hodgkin lymphoma (NHL) involving the uterine cervix is extremely 
rare with an incidence of 0.008% of all cervical tumors. Secondary involvement of the 
female genital tract as part of a systemic lymphoma is somewhat more common. Diffuse 
large-B-cell lymphoma (DLBCL), represents a classical ”high grade” NHL. Although 
this is one the most frequent lymphoid neoplasm of the cervix, its manifestation as a 
primary cervical tumor is considered a real rarity [1-4].  
The standard treatment for systemic DLBCL patients was the administration of 
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Since 1997, 
rituximab immunotherapy has been added to the CHOP regiment (R-CHOP), and has 
resulted in a significant improvement in the survival rate of these patients [5,6]. Because 
of the low incidence of primary NHLs in the female genital tract (reflected by only scarce 
case reports) there is no wide enough multicenter experience regarding their best complex 
treatment. It is unknown whether chemotherapy alone or in combination with 
radiotherapy or surgical interventions such as hysterectomy, pelvic node dissection or 
salpingo-oophorectomy would be the optimal therapeutic approach to this group of 
diseases.  Although R-CHOP could be considered the first-line regimen with promising 
results, a larger number of reported cases are needed to reach better founded conclusions 
[1,4,7-9].  
The aim of the present case report is to document a rare clinical entity: a 27-year-
old multipara incidentally diagnosed with DLBCL (WHO, CD20 positive) infiltrating the 
mucosa of the endocervix who was given R-CHOP therapy, responded well, and is 
without evidence of disease after 36 months of follow-up.  
 
 
CASE REPORT:  
 
The patient’s actual history started with a routine cancer screening, 48 months 
after her second delivery at the Department of Obstetrics and Gynecology, Bács–Kiskun 
County Teaching Hospital, Kecskemét, Hungary.  
The cervical cytology (Pap smear) was interpreted as representing low-grade 
squamous intraepithelial lesion (L-SIL, Cervical Intraepithelial Neoplasia grade 1, CIN 
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1) according to the Bethesda system. Colposcopic examination showed no specific signs 
and cytologic features raised the possibility of chronic endocervicitis with Human 
Papillomavirus (HPV) infection. According to the recommendation of the cytopathologist 
in this case, repeated cervical cytology taken at 3 months interval resulted in LSIL / CIN 
1 again, with HPV negativity on the basis of HPV typing performed at an outside 
laboratory, and LLETZ (large loop excision of the transformation zone) was performed. 
The cone was 6 mm deep, i.e. somewhat less than the 10 mm suggested for obtaining 
clear margins most of the time [10]. Histological results from the cone biopsy confirmed 
the presence of cervical intraepithelial neoplasia grade I (CIN I) with koilocytic atypia 
and p16 immunohistological staining of the dysplastic cells suggestive of HPV infection 
and also established the diagnosis of DLBCL infiltrating the mucosa of the endocervix  
(Figure 1). The CIN I lesion was present in 4 out of 9 histology blocks (the margins were 
either clear or not assessable), whereas the lymphoma involved 5 blocks and was almost 
exclusively present in the endocervical part of the biopsy, under the superficial glandular 
epithelium, around the galnds (the margins being involved). The lymphoma cells were 
negative for cytokeratin, CD5, and stained positive for CD20 and MUM1, consistent with 
the activated B-like subtype of DLBCL. The Ki-67 labeling index of the tumor cells was 
estimated and reported 70%.  
On physical examination, no spleno- or hepatomegaly was detected. Only some 
minimally enlarged lymph nodes, all smaller than 1 cm, were found inguinally on both 
sides. Although no detectable mass was found during initial colposcopy and physical 
examination, the pelvic MRI described an abnormal soft tissue mass measuring 6.5 x 2.3 
x 1.5 cm between the uterine corpus and the bladder at the time of the diagnosis. B signs 
were absent. Staging FDG-PET CT and pelvic MRI were performed, and did not indicate 
any myometrial, nodal or other organ involvement, thus, the patient’s DLBCL was 
categorized as stage IE according to the Ann Arbor staging system. The international 
prognostic index (IPI) was 0, and the Eastern Cooperative Oncology Group (ECOG) 
performance status was 0 too.  
After the proper diagnosis had been set up, six cycles of rituximab combined with 
standard CHOP chemotherapy (R-CHOP 21) were administered. In details, the dose of 
rituximab was 375 mg/m2, that of cyclophosphamide was 750 mg/m2, and that of 
doxorubicin was 50 mg/m2; vincristine was given in a dose of 1.4 mg/m2 on the first day 
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of the cycles, and 100 mg of prednisone was also taken orally from the first to the fifth 
day of each cycle. The administered therapeutic regimen was planned according to the 
risk based on the age-adjusted IPI. During the period of the treatment, there were no 
serious complications. The patient had reached partial remission four months after the 
introduction of the first cycle of R-CHOP 21 chemotherapy. The dimensions of the pelvic 
mass have significantly decreased.  As a consequence, the corpus of the uterus had 
become anteflected. Three months after the completion of R-CHOP 21 therapy, no 
circumscribed abnormality could be identified between the corpus and the bladder on the 
pelvic MRI scan.  
After the completion of the immuno-chemotherapy, repeated cervical cytology 
was done. FDG-PET CT and pelvic MRI were also performed, and confirmed the 
patient’s complete remission (by the Cheson criteria) [11]. 
14 months after the completion of chemotherapy, the patient became pregnant 
spontaneously, but the pregnancy was miscarried due to unknown reasons on the 8th 
week. After 36 months of follow-up, the patient is without any evidence of disease. 
 
DISCUSSION:  
 
R-CHOP therapy of some subsets of non-Hodgkin lymphoma (NHL) patients 
significantly improved their event-free and overall survivals [5].  However, there are only 
limited data available on the R-CHOP immune-chemotherapy of primary NHL of the 
female genital tract [7,12,13]. Vaginal bleeding is the most frequent primary symptom of 
genital lymphomas, but other symptoms such as abdominal pain or urinary complaints 
can also appear.  The most common clinical finding is the presence of a vaginal, 
cervicovaginal or pelvic mass [8,9,14,15]. The identification of the tumor is easier if 
colposcopy reveals a mass in the uterine cervix. For example, Binesh et al have reported 
a cervical mass identified by colposcopy, but no other lesions were detected in the case 
they described [13]. When primary DLBCL appears without a bulky disease, the 
identification and the diagnosis of the tumor is more difficult. The present case was 
unusual in several respects, as no detectable mass or any other colposcopic lesions were 
identified. The patient had no vaginal bleeding or other symptoms which could have 
referred to the underlying lymphoma, which was a chance finding following further 
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investigation of a cervical smear disclosing a low grade squamous intraepithelial lesion. 
Al-Talib et al. have also reported a case of high grade B cell lymphoma of the uterine 
cervix. They discuss the cytology features and the differential diagnosis with emphasis 
not just on the importance of the cervical biopsy but on also the potential role of the 
cervical smear in the initial diagnosis of this tumour [16]. Grace  et al. highlight the 
difficulty of diagnosing cervical lymphoma in the two cases they present,  and suggest 
that cervical biopsy is needed to establish the diagnosis [3].  
In line with previous reports, it can be concluded that vaginal bleeding and a mass 
in the uterine cervix can be the first signs of the disease in most cases, but as our case 
report shows there may be exceptions too [8,17]. Cervical lymphomas are initially 
subepithelial, therefore, there is a danger of underdiagnosis with cervical cytology, 
especially in the early stages. Cytology is unlikely to detect NHL, unless the disease has 
progressed to the epithelium, and biopsy is generally required to establish the proper 
diagnosis, as in the present case, where a coexisting low grade squamous intraepithelial 
lesion initiated the biopsy.  Based on previously reported cases, primary DLBCL of the 
female genital tract can occur at any age. With the introduction of immuno-chemotherapy, 
we could hope for a promising result regarding the disease free survival, but this 
introduces another important challenge: how to preserve the childbearing potential [1,18-
19]. There are only limited data on the recommended time of contraception, on the risk 
of miscarriages, or on the pregnancy outcome of women with and after R-CHOP immune-
chemotherapy in primary NHL of the female genital tract [1,18,19]. 
There are some data indicating that CHOP chemotherapy may be given safely to 
NHL patients in the third trimester of pregnancy [18]. Lorusso et al. have reported a 29-
year-old woman who was treated with neoadjuvant chemotherapy and conservative 
surgery for a primary stage IE non-Hodgkin  lymphoma of the uterine cervix in whom 
pregnancy was possible three years after the primary treatment, and the patient 
successfully delivered a full-term healthy infant [1]. In contrast, our patient had become 
spontaneously pregnant 14 months after chemotherapy, but experienced missed abortion. 
It can be speculated that previous chemotherapy had an influence on the termination of 
pregnancy, but the opposite may also hold true.  
 
Conclusion: 
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Primary cervical lymphomas are initially localized and subepithelial; therefore 
cervical cytology has only a limited role in establishing the proper diagnosis, which can 
be best made on the basis of LLETZ. Although in this case, the patient's management 
deviated from standard gynecological cancer screening protocols, this led to reveal the 
hidden disease at an early stage, and this chance finding led to further treatments which 
can contribute to the widening experience in the treatment of organ specific, localized 
NHLs in the female genital tract. In terms of therapy, our case report supports the notion 
that R-CHOP can be considered as first-line regimen with promising results in these rare 
manifestations of DLBCL as well. The interest in the case lies not only in its rarity, but 
also in the fact that our patient recovered from the disease without hysterectomy.  
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Figure 1:  Histological appearance of the squamous intraepithelial lesion and the high 
grade lymphoma involving the cervix. 
 
A: Low grade squamous intraepithelial lesion with koilocytic atypia in the upper third of the epithelium 
(HE, x400);  
B: Low grade squamous intraepithelial lesion with p16 positive cell (seen as light brown) restricted to the 
dysplastic cells (p16, x100);  
C and D: DLBCL around a cervical gland (HE and CD20, respectively; x400) 
 
